Immune Design: Q3 2015 Results (Immune Design) - Nov 15, 2015 - Anticipated clinical and immunogenicity data from the first six patients of dose escalation part and from a subset of patients of the expansion part of P1b (NCT02387125) study in metastatic cancer in Q1 2016; Anticipated data from P2 trial of CMB305 in combination atezolizumab in metastatic soft tissue sarcoma in H2 2016
Anticipated P1 data • Anticipated P2 data • Oncology
|